Mona Lisa Robotic Prostate Biopsy and Ablation System

Biobot Surgical is a Singapore-based medical technology company that makes robotic systems for transperineal prostate procedures. Its customers are hospitals and urology centres rather than patients. The company's website lists Mona Lisa DX, launched in 2017 for targeted biopsies, and Mona Lisa 2.0 TX, which adds soft tissue ablation.

The Mona Lisa platform combines robotic needle guidance with MRI-ultrasound image fusion, so a clinician can place a biopsy or ablation needle at a planned target through a transperineal route. The company reports more than 80 systems deployed worldwide and over 30,000 patients supported, with adoption at centres in Europe and Asia-Pacific.

• Robotic needle guidance: A robot holds and positions the biopsy or ablation needle along a planned trajectory.
• MRI-ultrasound fusion: Fused imaging lets clinicians target lesions identified on MRI.
• Transperineal access: Procedures are performed through the perineum rather than the rectum.
• Biopsy and ablation: Mona Lisa 2.0 TX extends the platform from diagnosis to soft tissue ablation.
• Regulatory clearances: The website lists FDA, CE, TGA, HSA and NMPA clearances across the product line.

Private and tertiary hospitals in Vietnam can use the system in urology and oncology centres for MRI-targeted prostate biopsy. Cancer centres can add focal ablation for selected patients. Distributors of medical equipment in Southeast Asia can partner on installation and training.

Hospitals gain a robotic option for targeted prostate biopsy and focal ablation within one platform. Image fusion supports targeting of lesions seen on MRI. The company cites more than 50 real-world clinical publications. Regulatory clearances listed on the website include FDA, CE, TGA and HSA, which eases procurement checks.

Prostate cancer detection is moving toward MRI-targeted biopsy and focal therapy, which favours image-guided robotic platforms. Hospitals in Vietnam and Southeast Asia are investing in urology and oncology capabilities, creating demand for precision diagnostic and minimally invasive equipment.

Singapore-based. Raised SGD 20 million in June 2026 led by ClavystBio (set up by Temasek) with ZIG Ventures, to fund US market entry together with Fogarty Innovation. Website lists more than 50 installed units on an earlier date and 5 regulatory clearances.